CONTEXT Studies comparing initial therapy for multisystem inflammatory syndrome in
children (MIS-C) provided conflicting results. OBJECTIVE To compare outcomes in MIS-C …

Background The assessment of real-world effectiveness of immunomodulatory medications
for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. Methods We …

Background Evidence is urgently needed to support treatment decisions for children with
multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory …

Importance Optimal agents and duration of primary treatment for multisystem inflammatory
syndrome in children (MIS-C) remain unclear. Objective To compare short-term patient …

Objective Two cohort studies in patients with multisystem inflammatory syndrome in children
(MIS‐C) demonstrated contrasting results regarding the benefit of initial immunomodulatory …

OBJECTIVES To compare initial treatment with intravenous immunoglobulin (IVIG) versus
IVIG plus infliximab in multisystem inflammatory syndrome in children (MIS-C). METHODS …

Scarce evidence exists about the best treatment for multi-system inflammatory syndrome
(MIS-C). We analyzed the effects of steroids, intravenous immunoglobulin (IVIG), and their …

Multisystem inflammatory syndrome in children (MIS-C) is a serious condition characterized
by excessive inflammation that can arise as a complication of SARS-CoV-2 infection in …

Importance Multisystem inflammatory syndrome in children (MIS-C) is the most severe
pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection …

Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory
condition associated with SARS-CoV-2 infection, has emerged as a serious illness in …